« Back
Parent Project Muscular Dystrophy and Sarepta Therapeutics Join Forces on Genetic Testing Program for Patients With Duchenne Muscular Dystrophy
10/17/13 8:30 AM EDT
Through the new program, called Decode Duchenne, PPMD will offer genetic testing at no cost to eligible patients who are unable to access testing due to barriers such as a lack of or insufficient insurance coverage. Decode Duchenne is expected to launch in the fourth quarter of 2013 through PPMD's DuchenneConnect, an online resource and registry for patients and families affected by Duchenne and their healthcare providers. For patients with Duchenne, genetic testing is used to identify the genetic mutation and confirm the diagnosis. In addition, genetic testing can be used to determine a patient's eligibility for certain clinical trials. Despite the potential benefits of testing, in some cases patients are unable to access genetic testing through their insurance provider.
"We believe all patients with Duchenne should have the opportunity to receive genetic testing in order to understand their genetic mutation, have confidence in their diagnosis and learn about opportunities to participate in clinical trials of promising investigational treatments," said
"We are pleased to support Decode Duchenne, an important initiative from PPMD and DuchenneConnect to help families and their physicians navigate a sometimes difficult process to receive genetic testing," said
To participate in Decode Duchenne, patients must:
- Have a confirmed diagnosis or be suspected of having Duchenne or Becker muscular dystrophy based on clinical symptoms, as assessed by their treating physician, and have a positive creatine kinase (CK) test.
- Have not previously had genetic testing, or must require additional genetic testing to identify a causative mutation, as determined by the DuchenneConnect Coordinator, a board-certified genetic counselor.
- Provide documentation to confirm the patient's lack of insurance coverage, insufficient insurance coverage, or a denial of coverage for genetic testing.
- Be citizens or legal residents of
the United States . - Register on DuchenneConnect.
Additional eligibility criteria may apply, and the DuchenneConnect Coordinator can help interested patients and their families determine if they are eligible to participate.
Patients and families can learn more about the Decode Duchenne genetic testing program by visiting DuchenneConnect at www.duchenneconnect.org, or by contacting the DuchenneConnect Coordinator at coordinator@duchenneconnect.org or (201) 937-1408. Information is also available through Sarepta's new online resource center Let's Skip Ahead, which is available at www.skipahead.com.
About DuchenneConnect
DuchenneConnect is a robust and cutting-edge registry and resource that serves the needs of the Duchenne and Becker community. The purpose of DuchenneConnect is to connect Duchenne and Becker patients with actively recruiting clinical trials and research studies, and to educate patients and families about Duchenne and Becker care and research. At the same time, DuchenneConnect is a valuable resource for clinicians and researchers in academia and industry, allowing access to aggregated, de-identified information provided by patients and their families -- information that is vital to advances in the care and treatment of Duchenne.
DuchenneConnect was created in 2007 by Parent Project Muscular Dystrophy (PPMD), with assistance from the
About Parent Project Muscular Dystrophy
Duchenne is a fatal genetic disorder that slowly robs young men of their muscle strength. Parent Project Muscular Dystrophy (PPMD) is the largest, most comprehensive nonprofit organization in
We invest deeply in treatments for this generation of young men affected by Duchenne and in research that will benefit future generations. We advocate in
Everything we do -- and everything we have done since our founding in 1994 -- helps boys with Duchenne live longer, stronger lives. We will not rest until every young man has a treatment to end Duchenne. Go to www.parentprojectmd.org for more information or to learn how you can support our efforts and help families affected by Duchenne.
About
PPMD Media Contact:
201.250.8440
Email Contact
Sarepta Media Contact:
857.242.3710
Email Contact
Sarepta Investor Contact:
857.242.3714
Email Contact
Source:
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.